Sundew completes fundraising
Sundew has completed a financing, with EIFO, The Yield Lab Europe and SOSV providing the funds.
Biotech ventures are a major source for novel therapeutics. There have been, will continue to be, many successes. And the business model (so long as the underlying biology works) is well established. We are involved in a few such ventures ourselves.
But our heart lies on the road less travelled. Where are the opportunities outside core therapeutics? What are the most robust business models for such businesses? How can life-science ventures best play a wider role in meeting the challenges of the modern world?
Co-Founder
Neil is a serial entrepreneur with broad experience of the life science sector. Founder or otherwise instrumental in the early development of multiple ventures over 35+ years, including Evolva (CH), Topotarget (DK), Biotage (SE), PNA Diagnostics (DK), BIAcore (SE), Quadrant (UK) & Scientific Generics (UK). Six have so far achieved stock market listings, five trade sale exit, with a few failures along the way.
Co-Founder
Andy has more than twenty five years’ experience of forming and running early-stage biotech companies, mainly in CEO and CFO roles. He had four years as CEO of crop-protection start-up InSecta and has been CEO of Norfolk Plant Sciences, a UK company focused on tomato genetics. Helped to build digital consultancy Seven League in both MD and FD roles. He has been involved in companies in UK, Denmark, Spain, Portugal and Slovakia.
Sundew has completed a financing, with EIFO, The Yield Lab Europe and SOSV providing the funds.
The Danish pharma giant joins Roche, J&J, CSL Behring, Pureos, CMS, Roivant and Bridge Biotherapeutics in supporting BaseLaunch’s development of innovative biotech companies.
Alentis is a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis. They announced today the first patient dosed in a Phase 2 clinical trial of lixudebart for the treatment of organ fibrosis.
T3 Pharma, which uses live bacteria to deliver immune-modulating proteins to cancer cells, has been acquired for up to 450M Swiss francs.
American distributor, LiveAquaria, has launched ‘ProtoPro’ the world’s first product based on Sundew’s proprietary active: Biokos™.
The Danish pharma giant joins Roche, J&J, CSL Behring, Pureos, CMS, Roivant and Bridge Biotherapeutics in supporting BaseLaunch’s development of innovative biotech companies